Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
4 reports, 2 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.Sub-event
Omeros submitted BLA for narsoplimab approval to the FDA.1 source
Keep exploring
The entities involved
-
Omeros Corporation
company in Seattle, United States
Nothing else this week.
- FDA
Related events
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
Coverage
Newest first; wire copies grouped- Business WireOmeros Corporation Reports Second Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, August 14, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced r
- ACCESS NewswireD. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering NEW YORK CITY, NEW YORK / ACCESS Newswire / July
- Unknown outlet
- Unknown outlet